Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate/salmeterol 250/50mcg inhalation powder administered twice daily in uncontrolled asthmatic subjects \> or = 18 years of age over the course of 6 weeks treatment.

The secondary objectives are to undertake an exploratory analysis of the efficacy and safety of adding montelukast 10mg administered once daily to fluticasone propionate/salmeterol 250/50mcg inhalation powder administered twice daily and to investigate the pharmacokinetics and pharmacodynamics of GSK2190915 in uncontrolled asthmatic subjects \> or = 18 years of age over the course of 6 weeks treatment.


Options:
A: Arm Label: FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: GSK2190915 200mg QD (AM), Drug: GSK2190915 100mg QD (AM), Drug: Placebo capsule (PM) | Arm Label: FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM); Type: ACTIVE_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Montelukast 10mg QD (PM), Drug: Placebo tablets (2) (AM) | Arm Label: FP/SAL 250/50mcg BID plus placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Placebo tablets (2) (AM), Drug: Placebo capsule (PM) | Intervention Type: DRUG; Name: FP/SAL 250/50mcg BID; Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: GSK2190915 200mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: GSK2190915 100mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: Montelukast 10mg QD (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM) | Intervention Type: DRUG; Name: Placebo tablets (2) (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: Placebo capsule (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus placebo BID
B: Arm Label: FP 100mcg BID plus GSK2190915 100mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP 100, Drug: GSK2190915 100 | Arm Label: FP 100mcg BID plus GSK2190915 300mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP 100, Drug: GSK2190915 300 | Arm Label: FP 100mcg BID plus montelukast 10mg QD (PM); Type: ACTIVE_COMPARATOR; Interventions: Drug: FP 100, Drug: montelukast | Arm Label: FP 100mcg BID plus placebo BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: FP 100, Drug: placebo | Arm Label: FP/SAL 100/50mcg BID plus placebo BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo, Drug: FP/SAL 100/50 | Intervention Type: DRUG; Name: FP 100; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 100mg QD (AM), FP 100mcg BID plus GSK2190915 300mg QD (AM), FP 100mcg BID plus montelukast 10mg QD (PM), FP 100mcg BID plus placebo BID | Intervention Type: DRUG; Name: GSK2190915 100; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 100mg QD (AM) | Intervention Type: DRUG; Name: GSK2190915 300; Assigned to Arm(s): FP 100mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): FP 100mcg BID plus montelukast 10mg QD (PM) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): FP 100mcg BID plus placebo BID, FP/SAL 100/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: FP/SAL 100/50; Assigned to Arm(s): FP/SAL 100/50mcg BID plus placebo BID
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
D: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A